{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:28Z","timestamp":1790697928799,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":776,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Abbott Laboratories and Boston Scientific"},{"name":"Abbott Laboratories and Boston Scientific"},{"name":"Abbott Laboratories and Boston Scientific"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.jacc.2010.12.033","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T08:31:15Z","timestamp":1303288275000},"page":"2496-2504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients"],"prefix":"10.1016","volume":"57","author":[{"given":"Vanessa","family":"Rold\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Mui\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Miguel","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Hern\u00e1ndez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.jacc.2010.12.033_bib1","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kennel","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.12.033_bib2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.12.033_bib3","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2010.12.033_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1160\/TH09-11-0757","article-title":"The CHADS2 score for stroke risk stratification in atrial fibrillation\u2014friend or foe?","volume":"104","author":"Karthikeyan","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.12.033_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.12.033_bib6","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.12.033_bib7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"48","author":"Fuster","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.12.033_bib8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjmed.2010.01.031","article-title":"Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?","volume":"123","author":"Lip","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2010.12.033_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00001721-199806000-00001","article-title":"The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications","volume":"9","author":"Blann","year":"1998","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacc.2010.12.033_bib10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(95)92339-X","article-title":"Does atrial fibrillation confer a hypercoagulable state?","volume":"346","author":"Lip","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.12.033_bib11","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/01.CIR.0000033220.97592.9A","article-title":"Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors","volume":"106","author":"Conway","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.12.033_bib12","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1161\/01.CIR.0000077912.12202.FC","article-title":"Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation","volume":"107","author":"Conway","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.12.033_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.thromres.2005.01.005","article-title":"Correlation of plasma von Willebrand factor levels, an index of endothelial damage\/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation","volume":"116","author":"Rold\u00e1n","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2010.12.033_bib14","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1161\/ATVBAHA.107.152777","article-title":"Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation","volume":"27","author":"Ferro","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.12.033_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.amjcard.2010.03.067","article-title":"Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation","volume":"106","author":"Maehama","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.12.033_bib16","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2009.12.049","article-title":"Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy","volume":"55","author":"Sadanaga","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.12.033_bib17","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1160\/TH03-06-0363","article-title":"High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy","volume":"90","author":"Vene","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.12.033_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.mbc.0000114440.81125.bd","article-title":"D-dimer can predict survival in patients with chronic atrial fibrillation","volume":"15","author":"Mah\u00e9","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jacc.2010.12.033_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/qjmed\/hcm076","article-title":"Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review","volume":"100","author":"Hughes","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.jacc.2010.12.033_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.12.033_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.12.033_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.12.033_bib23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/clinchem\/39.4.561","article-title":"Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine","volume":"39","author":"Zweig","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2010.12.033_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"issue":"Suppl","key":"10.1016\/j.jacc.2010.12.033_bib25","first-page":"311","article-title":"The CHADS2 score predicts adverse cardiovascular outcome in atherothrombotic patients without atrial fibrillation: insights from the European REACH registry (abstr)","volume":"30","author":"Barthelemy","year":"2009","journal-title":"Eur Heart J"},{"issue":"Suppl 6","key":"10.1016\/j.jacc.2010.12.033_bib26","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.12.033_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11739-010-0352-2","article-title":"The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue","volume":"5","author":"Polimeli","year":"2010","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jacc.2010.12.033_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.12.033_bib29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","article-title":"Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis","volume":"156","author":"Goto","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2010.12.033_bib30","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","article-title":"Von Willebrand factor, endothelial dysfunction, and cardiovascular disease","volume":"4","author":"Vischer","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2010.12.033_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.12.033_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0037-1617102","article-title":"The endothelium and atrial fibrillation","volume":"28","author":"Freestone","year":"2008","journal-title":"H\u00e4emostaseologie"},{"key":"10.1016\/j.jacc.2010.12.033_bib33","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1161\/01.STR.0000236840.00467.84","article-title":"Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation","volume":"37","author":"Lip","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.12.033_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.722827","article-title":"Von Willebrand factor in cardiovascular disease","volume":"117","author":"Spiel","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.12.033_bib35","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"issue":"Suppl 6","key":"10.1016\/j.jacc.2010.12.033_bib36","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"133","author":"Schulman","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2010.12.033_bib37","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"Fang","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.12.033_bib38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2009.05.046","article-title":"Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years","volume":"54","author":"Poli","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.12.033_bib39","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.12.033_bib40","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1161\/01.STR.0000141933.75462.c2","article-title":"Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients","volume":"35","author":"Shireman","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.12.033_bib41","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/STROKEAHA.107.500199","article-title":"Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W)","volume":"39","author":"Healey","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.12.033_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/qjmed\/hcm076","article-title":"Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review","volume":"100","author":"Hughes","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.jacc.2010.12.033_bib43","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1378\/chest.08-1425","article-title":"Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting","volume":"135","author":"Manzano-Fern\u00e1ndez","year":"2009","journal-title":"Chest"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109711009740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109711009740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:44:46Z","timestamp":1760013886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109711009740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":43,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0735109711009740"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.12.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}